The DOI matches its Crossref record.
WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma.
Abstract
Cisplatin, alone or in combination with other chemotherapeutic agents, is relatively inactive against metastatic melanoma. Prior trials have demonstrated partial response (PR) rates of less than 10% with cisplatin alone. WR-2721 is an organic thiophosphate compound, which in the animal model, selectively protects normal tissues against the toxicity of cisplatin chemotherapy. During the course of a phase I trial of WR-2721 and cisplatin, objective PRs were noted in patients with far advanced metastatic melanoma. These observations led us to perform a phase II trial of WR-2721 and cisplatin. Thirty-six patients received 128 courses of WR-2721 before cisplatin (60 to 150 mg/m2). All patients had progressive disease before treatment. Objective PRs were observed in 19 of 36 evaluable patients (53%). Three additional patients had minor responses (MRs). PRs occurred in 53% of patients with prior chemotherapy (ten of 19). Sites of responding metastases were subcutaneous disease (15 of 19 patients), lymph nodes (16 of 21 patients), lung (four of ten patients), and liver (eight of 17 patients). The median duration of response was 4 months, with a mean of 4.5 months (range, 1 to 8 months). Transient nephrotoxicity was observed in less than 5% of courses. In all cases, renal function returned to normal within 1 to 2 weeks. Hematologic toxicity was mild and infrequent. Nine patients developed peripheral neuropathy following a median cisplatin dose of 670 mg/m2. Twenty patients experienced mild clinical hearing loss. These data suggest that WR-2721 may potentiate the antitumor activity of cisplatin in metastatic melanoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Strategies for optimizing the response of cancer and normal tissues to radiation
Moding, E. J., Kastan, M. B., & Kirsch, D. G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4003 · Cited by 461
Hensley, M. L., Schuchter, L., Lindley, C., Meropol, N., Cohen, G., Broder, G., Gradishar, W., Green, D., Langdon, R., Mitchell, R. B., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.10.3333 · Cited by 335
Interventions for preventing neuropathy caused by cisplatin and related compounds
Albers, J. W., Chaudhry, V., Cavaletti, G., & Donehower, R. C. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005228.pub4 · Cited by 298
SEVERE NEUROTOXICITY, OTOTOXICITY AND NEPHROTOXICITY FOLLOWING HIGH-DOSE CISPLATIN AND AMIFOSTINE
Sastry, J., & Kellie, S. J. (2005) · Pediatric Hematology and Oncology · doi:10.1080/08880010590964381 · Cited by 258
Reducing the toxicity of anticancer therapy: New strategies
Griggs, J. J. (1998) · Leukemia Research · doi:10.1016/s0145-2126(98)00036-8 · Cited by 48
Metadata
- Authors
- Glover, D., Glick, J. H., Weiler, C., Fox, K., & Guerry, D.
- Venue
- Journal of Clinical Oncology
- Published
- 1987-04
- Volume
- 5
- Issue
- 4
- Pages
- 574-578
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2252830758
- Cited by
- 192
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. https://app.cochat.ai/papers/10.1200/jco.1987.5.4.574
- The paper
- Glover, D., Glick, J. H., Weiler, C., Fox, K., & Guerry, D. (1987). WR-2721 and high-dose cisplatin: an active combination in the treatment of metastatic melanoma. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1987.5.4.574
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.